Heartseed has set a mission to “open the door to heart disease treatment with regenerative medicine”.
Heartseed has set a mission to “open the door to heart disease treatment with regenerative medicine” and is working toward the day-to-day clinical application of myocardial regenerative medicine.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 11, 2021 | Series C | $37M | 9 | — | — | Detail |
Mar 10, 2020 | Corporate Round | ¥100.34M | 2 | — | — | Detail |
Nov 21, 2019 | Series B | $26M | 6 | — | — | Detail |
Jul 30, 2018 | Series A | ¥800M | 3 | Angel Bridge | — | Detail |
Mar 14, 2016 | Seed | ¥100M | 1 | Angel Bridge | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Angel Bridge | Yes | Series A |
ITOCHU Chemical Frontier | — | Series C |
Keio Innovation Initiative | — | Series C |
Medical Incubator Japan | — | Series C |
Medipal Holdings | — | Series C |
Nissay Capital | — | Series C |
SBI Group | — | Series C |
SMBC Venture Capital | — | Series C |
Sumitomo Mitsui Trust Investment | — | Series C |
UTokyo Innovation Platform | — | Series C |